Senior Scientist/Assoc. Director, Translational Medicine (Clinical Biomarker and Diagnostics)

94080, South San Francisco
Jun 16, 2021
Required Education
Position Type
Full time

Harpoon Therapeutics (ticker: HARP) is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for cancers expressing DLL3, initially focused on small cell lung cancer and other tumors with high-grade neuroendocrine features. Harpoon is led by an experienced management team. The company emphasizes a collegial, collaborative environment and has a strong record of scientific innovation, pioneering protein engineering, expertise in tumor immunology and pre-clinical and clinical research. For additional information about Harpoon Therapeutics, please visit

We are seeking a highly motivated individual to lead the development, execution, and data analysis of exploratory pharmacodynamic (PD) endpoint and biomarkers as well as companion diagnostic strategies for multiple clinical development programs.


  • Provide scientific leadership in diagnostics development
  • Contribute to the development and execution of clinical Biomarker / companion diagnostics strategies as part of drug development
  • Collaborate with members of Product Development Team (PDT) and outside CROs to drive and implement program-specific diagnostics strategies for clinical development molecules
  • Develop diagnostics related regulatory strategies and participate in interactions with health authorities
  • Represent PDT on diagnostics related activities in decision-making committees such as executive management and board of directors
  • Contribute to scientific presentations and publications targeted to the scientific and biotech community


  • PhD in a relevant field of biomedical research, e.g., cancer biology, cell biology, molecular biology, pharmacology, or immunology with at least 5 years post-doctoral experience in industry/academic setting (title commensurate with experience)
  • Expertise and hands on experience in cancer drug target discovery, characterization, and validation utilizing various cell-, protein-, and/or transcript-based experimental techniques that may include immunohistochemistry, immunofluorescence microscopy, flow cytometry, in vivo imaging, and/or gene expression profiling
  • Experience in diagnostics development for patient selection, pharmacodynamic marker evaluation, and regulatory knowledge in diagnostics development are major pluses
  • Industry experience in cancer immunotherapy, translational science and biomarker development is preferred
  • Excellent verbal and written communication; strong organizational and interpersonal skills
  • Ability to establish priorities, operate with a sense of urgency in a dynamic, fast-paced, timeline-driven environment